$BIOA 8-K SEC Filings

Filed On	Filing
02 Oct 2026	8-K: Other Events BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e...
05 Aug 2026	8-K: Results of Operations and Financial Condition
12 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
08 May 2026	8-K: Results of Operations and Financial Condition
24 Mar 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
22 Jan 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
20 Jan 2026	8-K: Regulation FD Disclosure; Other Events
12 Jan 2026	8-K: Regulation FD Disclosure; Other Events
04 Dec 2025	8-K: Regulation FD Disclosure; Other Events
06 Nov 2025	8-K: Results of Operations and Financial Condition
06 Aug 2025	8-K: Results of Operations and Financial Condition
09 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
04 Jun 2025	8-K: Other Events
06 May 2025	8-K: Results of Operations and Financial Condition
20 Mar 2025	8-K: Results of Operations and Financial Condition
07 Nov 2024	8-K: Results of Operations and Financial Condition
27 Sep 2024	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

Comments